[{"title": "Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.'", "url": "https://www.msn.com/en-us/money/general/zevra-therapeutics-crashes-reversing-89-run-why-it-could-be-an-overreaction/ar-AA1KspxR", "snippet": "Zevra Therapeutics stock crashed Wednesday in what one analyst called an \"overreaction\" to issues surrounding its acquired drug, Olpruva.", "published": "2025-08-13T18:57:00+00:00"}, {"title": "Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...", "url": "https://finance.yahoo.com/news/zevra-therapeutics-inc-zvra-q2-071122041.html", "snippet": "Zevra Therapeutics Inc (ZVRA) reports robust Q2 performance with significant revenue growth and strategic advancements, despite facing market adoption challenges for new treatments.", "published": "2025-08-13T07:36:00+00:00"}, {"title": "Zevra Therapeutics: Q2 Earnings Snapshot", "url": "https://www.timesunion.com/business/article/zevra-therapeutics-q2-earnings-snapshot-20814666.php", "snippet": "CELEBRATION, Fla. (AP) \u2014 CELEBRATION, Fla. (AP) \u2014 Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported second-quarter net income of $74.7 million. The Celebration, Florida-based company said it had profit of $1.21 per share. Losses, adjusted for non-recurring gains, came to 6 cents per share.", "published": "2025-08-12T20:49:00+00:00"}, {"title": "Zevra Therapeutics falls as significant earnings miss overshadows revenue beat", "url": "https://www.investing.com/news/earnings/zevra-therapeutics-falls-as-significant-earnings-miss-overshadows-revenue-beat-93CH-4186478", "snippet": "The company reported adjusted earnings per share of -$0.06 for the second quarter, falling well short of the analyst consensus estimate of $2.19. Revenue came in at $25.9 million, surpassing the consensus estimate of $22.49 million and showing substantial growth from $4.4 million in the same quarter last year.", "published": "2025-08-12T20:28:00+00:00"}]